Updated overall survival analysis from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
An expert discusses updated overall survival results from the phase 2 PHAROS study evaluating encorafenib plus binimetinib in patients with BRAF V600E–mutant metastatic non–small cell lung cancer (mNSCLC).
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.